

Charles Leath Iii

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4327523/publications.pdf>

Version: 2024-02-01

112
papers

3,010
citations

196777

29
h-index

206121

51
g-index

113
all docs

113
docs citations

113
times ranked

3400
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of Delivery Systems for Local Administration of Cytokines/Cytokine Gene-Directed Therapeutics: Modern Oncologic Implications. <i>Current Oncology Reports</i> , 2022, 24, 389-397.	1.8	5
2	Barriers and facilitators affecting presentation in women with early versus advanced stage cervical cancer. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100950.	0.3	1
3	Fluorescence Imaging of the Ureter in Minimally Invasive Pelvic Surgery. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 332-341.e14.	0.3	5
4	Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 191-226.	2.3	356
5	GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study. <i>Clinical Cancer Research</i> , 2021, 27, 5536-5545.	3.2	15
6	Systematic Next Generation Sequencing is feasible in clinical practice and identifies opportunities for targeted therapy in women with uterine cancer: Results from a prospective cohort study. <i>Gynecologic Oncology</i> , 2021, 163, 85-92.	0.6	8
7	Identifying a molecular profile to predict the risk of recurrence in high-intermediate risk endometrial cancer. <i>Cancer Medicine</i> , 2021, 10, 8238-8250.	1.3	2
8	Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020, 158, 562-569.	0.6	35
9	Decreasing opioid use in postoperative gynecologic oncology patients through a restrictive opioid prescribing algorithm. <i>Gynecologic Oncology</i> , 2020, 159, 773-777.	0.6	11
10	Bowel Perforation in the Emergency Department Related to Bevacizumab Therapy and Recurrent Ovarian Cancer. <i>Clinical Practice and Cases in Emergency Medicine</i> , 2020, 4, 227-229.	0.1	2
11	A Multi-atlas Approach for Active Bone Marrow Sparing Radiation Therapy: Implementation in the NRG-GY006 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1240-1247.	0.4	13
12	Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy. <i>Drugs</i> , 2020, 80, 217-227.	4.9	61
13	Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 12-16.	0.6	3
14	Pyridoxine for prevention and treatment of PARP inhibitor induced nausea and vomiting. <i>Gynecologic Oncology Reports</i> , 2019, 29, 123-125.	0.3	3
15	Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation. <i>Gynecologic Oncology</i> , 2019, 155, 365-373.	0.6	9
16	Assessing recurrence risk following intraperitoneal chemotherapy for ovarian cancer: A day late and a dollar short?. <i>Gynecologic Oncology Reports</i> , 2019, 29, 111-112.	0.3	1
17	Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic. <i>Gynecologic Oncology</i> , 2019, 154, 379-382.	0.6	7
18	Comparative outcomes between robotic and abdominal radical hysterectomy for IB1 cervical cancer: Results from a single high volume institution. <i>Gynecologic Oncology</i> , 2019, 153, 242-247.	0.6	71

#	ARTICLE	IF	CITATIONS
19	Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 138-142.	0.6	5
20	The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction. <i>Gynecologic Oncology</i> , 2019, 152, 127-132.	0.6	28
21	Response to laparoscopic management of cervical cancer by laparoscopy or laparotomy. <i>Gynecologic Oncology Reports</i> , 2019, 27, 6-7.	0.3	1
22	Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. <i>Cancer Medicine</i> , 2018, 7, 616-625.	1.3	5
23	High Rates of High-Grade Cervical Dysplasia in High-Risk Young Women With Low-Grade Cervical Cytology. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 207-211.	0.9	4
24	Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?. <i>Gynecologic Oncology</i> , 2018, 149, 49-52.	0.6	11
25	Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma. <i>Molecular Cancer Research</i> , 2018, 16, 813-824.	1.5	42
26	Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic. <i>Gynecologic Oncology</i> , 2018, 149, 337-340.	0.6	6
27	The Impact of Racial, Geographic, and Socioeconomic Risk Factors on the Development of Advanced-Stage Cervical Cancer. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 269-273.	0.9	10
28	Impact of enhanced recovery after surgery (ERAS) protocol on gastrointestinal function in gynecologic oncology patients undergoing laparotomy. <i>Gynecologic Oncology</i> , 2018, 151, 282-286.	0.6	42
29	Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years. <i>Gynecologic Oncology</i> , 2018, 150, 391-397.	0.6	39
30	A Ketogenic Diet Reduces Central Obesity and Serum Insulin in Women with Ovarian or Endometrial Cancer. <i>Journal of Nutrition</i> , 2018, 148, 1253-1260.	1.3	96
31	Enhanced Recovery After Surgery in Surgical Specialties. <i>Surgical Clinics of North America</i> , 2018, 98, 1275-1285.	0.5	5
32	Malignant Brenner tumor associated with a germline BRCA2 mutation. <i>Gynecologic Oncology Reports</i> , 2017, 21, 17-19.	0.3	3
33	A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 291-297.	0.6	15
34	Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 120-124.	1.2	20
35	Drawing the Line in Risk-Reducing Gynecologic Surgery in Women With a BRCA Mutation. <i>JAMA Oncology</i> , 2016, 2, 1409.	3.4	3
36	See-and-Treat for High-Grade Cytology: Do Young Women Have Different Rates of High-Grade Histology?. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 243-246.	0.9	10

#	ARTICLE	IF	CITATIONS
37	Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016, 142, 25-29.	0.6	16
38	Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?. <i>Gynecologic Oncology</i> , 2016, 143, 617-621.	0.6	38
39	Does a Standardized Preoperative Algorithm of Clinical Data Improve Outcomes in Patients With Ovarian Cancer? A Quality Improvement Project. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 798-801.	1.2	5
40	Laparoscopic Staging of Ovarian Immature Teratomas: A Report on Three Cases. <i>Military Medicine</i> , 2015, 180, e365-e368.	0.4	2
41	The Impact of Diabetes on Gynecologic Cancer: Current Status and Future Directions. <i>Current Obstetrics and Gynecology Reports</i> , 2015, 4, 234-239.	0.3	17
42	Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: Is it cost-effective?. <i>Gynecologic Oncology</i> , 2015, 136, 43-47.	0.6	24
43	Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. <i>Gynecologic Oncology</i> , 2015, 138, 267-271.	0.6	11
44	PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2015, 139, 59-62.	0.6	45
45	A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 68.e1-68.e8.	0.7	17
46	Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center. <i>Gynecologic Oncology</i> , 2014, 133, 142-146.	0.6	50
47	Diabetes mellitus and ovarian cancer: More complex than just increasing risk. <i>Gynecologic Oncology</i> , 2014, 135, 273-277.	0.6	41
48	Black race independently predicts worse survival in uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2014, 133, 238-241.	0.6	26
49	Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma. <i>Gynecologic Oncology</i> , 2014, 133, 234-237.	0.6	17
50	Primary invasive breast carcinoma arising in mammary-like glands of the vulva managed with excision and sentinel lymph node biopsy. <i>Gynecologic Oncology Case Reports</i> , 2014, 7, 7-9.	0.9	11
51	Cost-effectiveness Analysis of Sentinel Lymph Node Biopsy in the Treatment of Early-Stage Vulvar Cancer. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1480-1485.	1.2	26
52	Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer. <i>Cancer</i> , 2013, 119, 3653-3661.	2.0	42
53	Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer?. <i>Gynecologic Oncology</i> , 2013, 130, 317-322.	0.6	10
54	Growing teratoma syndrome: Brief communication and algorithm for management. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2013, 53, 318-321.	0.4	13

#	ARTICLE	IF	CITATIONS
55	Chemotherapy for advanced and recurrent cervical carcinoma: Results from cooperative group trials. <i>Gynecologic Oncology</i> , 2013, 129, 251-257.	0.6	56
56	Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility. <i>Gynecologic Oncology</i> , 2013, 131, 158-162.	0.6	24
57	Malignant Pericardial Effusion and Pericardial Tumor Involvement Secondary to Cervical Cancer. <i>Military Medicine</i> , 2013, 178, e130-e132.	0.4	1
58	Comparison of operative risks associated with radical hysterectomy in pregnant and nonpregnant women. <i>Journal of reproductive medicine, The</i> , 2013, 58, 279-84.	0.2	2
59	Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix. <i>Gynecologic Oncology</i> , 2012, 127, 267-272.	0.6	12
60	Re: "The utilization of palliative care in gynecologic oncology patients near the end of life" <i>Gynecologic Oncology</i> , 2012, 127, 678-679.	0.6	0
61	Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 362-371.	0.8	204
62	Robotic surgery applications in the management of gynecologic malignancies. <i>Journal of Surgical Oncology</i> , 2012, 105, 481-487.	0.8	24
63	Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy. <i>Gynecologic Oncology</i> , 2012, 126, 69-72.	0.6	9
64	Reaction to a Surgical Implant Foreign Body Masquerading as Recurrent Uterine Sarcoma. <i>Obstetrics and Gynecology</i> , 2011, 117, 450-452.	1.2	6
65	Multiple synchronous primary ovarian malignancies in a patient with a MLH-1 mutation: Impact on potential fertility preservation. <i>Gynecologic Oncology</i> , 2011, 121, 637-638.	0.6	1
66	Erratum to "Hospice enrollment for terminally ill patients with gynecologic malignancies: Impact on outcomes and interventions" [<i>Gynecol. Oncol.</i> 118 (2010) 274-277]. <i>Gynecologic Oncology</i> , 2011, 121, 643.	0.6	0
67	Incidence of subsequent abnormal cytology in cervical cancer patients completing five-years of post treatment surveillance without evidence of recurrence. <i>Gynecologic Oncology</i> , 2011, 122, 501-504.	0.6	12
68	Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: A pilot study. <i>Gynecologic Oncology</i> , 2011, 123, 360-364.	0.6	23
69	Surgically managed stage I endometrial cancer in a low-volume center: outcomes and complications in a military residency program. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 356.e1-356.e5.	0.7	2
70	Epithelioid trophoblastic tumor masquerading as invasive squamous cell carcinoma of the cervix after an ectopic pregnancy. <i>Gynecologic Oncology</i> , 2010, 117, 387-388.	0.6	11
71	Hospice enrollment for terminally ill patients with gynecologic malignancies: Impact on outcomes and interventions. <i>Gynecologic Oncology</i> , 2010, 118, 274-277.	0.6	33
72	Undifferentiated Uterine Sarcoma Presenting as a Pathologic Humerus Fracture. <i>Military Medicine</i> , 2010, 175, 691-692.	0.4	1

#	ARTICLE	IF	CITATIONS
73	Cervical Signet-Ring Cell Carcinoma Presenting as a Synchronous Primary Carcinoma with Uterine Adenocarcinoma. <i>Military Medicine</i> , 2009, 174, 212-213.	0.4	3
74	Hot and blue. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 201, 223.e1-223.e2.	0.7	0
75	Patterns of Failure for Conservatively Managed Surgical Stage I Uterine Carcinosarcoma. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 888-891.	1.2	32
76	Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2008, 110, 268-269.	0.6	1
77	Conservative Management of Postoperative Fever in Gynecologic Patients Undergoing Major Abdominal or Vaginal Operations. <i>Journal of the American College of Surgeons</i> , 2008, 207, 393-397.	0.2	17
78	A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy. <i>Gynecologic Oncology</i> , 2007, 104, 591-595.	0.6	24
79	A multi-institutional review of outcomes of endometrial stromal sarcoma. <i>Gynecologic Oncology</i> , 2007, 105, 630-634.	0.6	187
80	Serous fallopian tube carcinoma: A retrospective, multi-institutional caseâ€“control comparison to serous adenocarcinoma of the ovary. <i>Gynecologic Oncology</i> , 2007, 107, 398-403.	0.6	50
81	Current controversies in the biology and management of ovarian tumors of low malignant potential. <i>Women's Oncology Review</i> , 2007, 6, 15-25.	0.0	0
82	Use of a Fascial Prosthesis for Management of Abdominal Compartment Syndrome Secondary to Obstetric Hemorrhage. <i>Obstetrics and Gynecology</i> , 2006, 107, 493-496.	1.2	7
83	Synchronous Primary Endometrial and Ovarian Carcinoma in a Patient With Marantic Endocarditis. <i>Obstetrics and Gynecology</i> , 2006, 108, 748-750.	1.2	10
84	Inflammatory Pseudotumor of Pelvic Lymph Nodes. <i>Obstetrics and Gynecology</i> , 2006, 108, 779-782.	1.2	3
85	Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 102, 338-342.	0.6	5
86	Bowel Resection at the Time of Primary Debulking for Epithelial Ovarian Carcinoma: Outcomes in Patients Treated with Platinum and Taxane-Based Chemotherapy. <i>Journal of the American College of Surgeons</i> , 2006, 203, 527-532.	0.2	54
87	Pegylated Liposomal Doxorubicin Consolidation Therapy after Platinum/Paclitaxelâ€“Based Chemotherapy for Suboptimally Debulked, Advancedâ€“Stage Epithelial Ovarian Cancer Patients. <i>Oncologist</i> , 2006, 11, 336-341.	1.9	14
88	Surgical staging in endometrial cancer. <i>Oncology</i> , 2006, 20, 45-50; discussion 50, 53-4, 63.	0.4	13
89	A Cost-Effectiveness Analysis of Screening Strategies for Cervical Intraepithelial Neoplasia. <i>Obstetrical and Gynecological Survey</i> , 2005, 60, 96-97.	0.2	0
90	A Prospective Evaluation of "See and Treat" in Women with HSIL Pap Smear Results: Is This an Appropriate Strategy?. <i>Journal of Lower Genital Tract Disease</i> , 2005, 9, 2-6.	0.9	47

#	ARTICLE	IF	CITATIONS
91	Management strategies for stage IB2 cervical cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2005, 97, 387-394.	0.6	31
92	Occult choriocarcinoma discovered by positron emission tomography/computed tomography imaging following a successful pregnancy. <i>Gynecologic Oncology</i> , 2005, 97, 713-715.	0.6	21
93	Predictors of outcomes for women with cervical carcinoma. <i>Gynecologic Oncology</i> , 2005, 99, 432-436.	0.6	28
94	Transcriptional Blocks Limit Adenoviral Replication in Primary Ovarian Tumor. <i>Clinical Cancer Research</i> , 2004, 10, 3189-3194.	3.2	8
95	Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. <i>Cancer Gene Therapy</i> , 2004, 11, 256-262.	2.2	99
96	The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomy. <i>Gynecologic Oncology</i> , 2004, 92, 215-219.	0.6	33
97	Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. <i>Gynecologic Oncology</i> , 2004, 93, 429-434.	0.6	57
98	Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinoma. <i>Gynecologic Oncology</i> , 2004, 94, 352-362.	0.6	28
99	Primary lung large cell carcinoma metastatic to the vulva: a case report and review of the literature. <i>Gynecologic Oncology</i> , 2004, 94, 829-831.	0.6	14
100	The impact of aborted radical hysterectomy in patients with cervical carcinoma. <i>Gynecologic Oncology</i> , 2004, 95, 204-207.	0.6	11
101	Protrusio Acetabuli Presenting as a Complex Pelvic Mass After Total Hip Arthroplasty. <i>Obstetrics and Gynecology</i> , 2004, 104, 1187-1189.	1.2	2
102	A Cost-Effectiveness Analysis of Screening Strategies for Cervical Intraepithelial Neoplasia. <i>Journal of Lower Genital Tract Disease</i> , 2004, 8, 280-284.	0.9	2
103	Single-chain antibodies: A therapeutic modality for cancer gene therapy (review). <i>International Journal of Oncology</i> , 2004, 24, 765-71.	1.4	5
104	Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series. <i>Journal of reproductive medicine, The</i> , 2004, 49, 71-5.	0.2	14
105	Complications of indwelling venous access devices in patients with gynecologic malignancies. <i>Gynecologic Oncology</i> , 2003, 91, 591-595.	0.6	16
106	Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. <i>Gynecologic Oncology</i> , 2003, 91, 470-475.	0.6	131
107	Primary extrarenal rhabdoid tumor of the ovary. A case report. <i>Journal of reproductive medicine, The</i> , 2003, 48, 283-6.	0.2	9
108	A Guest Editorial: Stump the Professor. <i>Obstetrical and Gynecological Survey</i> , 2002, 57, 785-787.	0.2	0

#	ARTICLE	IF	CITATIONS
109	Uterine leiomyosarcoma metastatic to the thyroid. <i>Obstetrics and Gynecology</i> , 2002, 100, 1122-1124.	1.2	31
110	Conservative Management of Stage I Endometrial Carcinoma after Surgical Staging. <i>Gynecologic Oncology</i> , 2002, 84, 194-200.	0.6	163
111	A Pilot Study of Ovarian Cancer Chemoprevention Using Medroxyprogesterone Acetate in an Avian Model of Spontaneous Ovarian Carcinogenesis. <i>Gynecologic Oncology</i> , 2002, 87, 57-63.	0.6	55
112	Feasibility, Safety, and Provider Perspectives of Bipolar Electrosurgical Cautery Device for (Opportunistic or Complete) Salpingectomy at the Time of Cesarean Delivery. <i>American Journal of Perinatology</i> , 0, , .	0.6	0